Cardiovascular disease claimed 19.8 million lives in 2022, according to the World Health Organization, making it the world’s leading cause of death — surpassing all cancers combined. Hypertension, or persistently elevated blood pressure, is the single most important modifiable risk factor driving this epidemic. As World Hypertension Day is marked globally, experts from Tehran to Jakarta are sounding the alarm that too few people realise they are at risk, and many avoid diagnosis altogether.

In Iran, Dr. Fereydoun Nouhi, head of the Shahid Rajaei Heart Hospital in Tehran, has warned that hypertension acts as a “silent killer” in the home, often undetected until it triggers stroke, kidney failure, or blindness. He noted that roughly three-quarters of all heart disease patients have high blood pressure, underscoring the urgency of routine screening. This message resonates across Asia: in Indonesia, the Ministry of Health’s director of non-communicable disease prevention, Siti Nadia Tarmizi, has identified low public awareness as the biggest barrier to control — many citizens refuse to check their pressure for fear of a diagnosis that carries social stigma.

Yet there are signs of a coordinated global push to counter the trend. The Merck Foundation, the philanthropic arm of the German pharmaceutical giant, marked the day by announcing nearly 1,000 scholarships for healthcare providers from 52 countries. These one- and two-year online postgraduate diplomas focus on cardiovascular prevention, cardiology, diabetes, and endocrinology. The foundation has also deployed a novel “Fashion and Art with Purpose” community across Africa and Asia, using creative media to destigmatise chronic disease and encourage screening — a strategy its CEO, Senator Dr. Rasha Kelej, has championed as transformative for social change.

A fresh debate over cholesterol — long portrayed as the primary villain in heart disease — is reshaping the preventive landscape. Colombian surgeon and functional medicine specialist Dr. Carlos Jaramillo argues that nearly half of those who suffer heart attacks have normal or low cholesterol levels. His book, provocatively titled *Your Friend Cholesterol*, insists that inflammation and metabolic health matter more than a single lipid number. Viewed from Latin America, this challenges long‑held assumptions and points to a need for more nuanced risk assessment in primary care.

Looking ahead, the battle against hypertension will require not only expanded treatment access but also a fundamental shift in public mindset. The Merck Foundation’s scholarship model, combined with community-level campaigns in places like Iran and Indonesia, offers a template for bridging the gap between clinical knowledge and everyday behaviour. But as the data from 2022 makes clear, the stakes could not be higher: without sustained investment in awareness and early detection, the silent killer will continue to claim millions.